Literature DB >> 30956174

Corrigendum to "Modulation of mitochondrial complex I activity averts cognitive decline in multiple animal models of familial Alzheimer's disease" [EBioMedicine 2 (2015) 294-305].

Liang Zhang1, Song Zhang2, Izumi Maezawa3, Sergey Trushin1, Paras Minhas1, Matthew Pinto1, Lee-Way Jin3, Keshar Prasain4, Thi D T Nguyen4, Yu Yamazaki5, Takahisa Kanekiyo5, Guojun Bu5, Benjamin Gateno1, Kyeong-Ok Chang6, Karl A Nath7, Emirhan Nemutlu8, Petras Dzeja2, Yuan-Ping Pang9, Duy H Hua4, Eugenia Trushina10.   

Abstract

Entities:  

Year:  2019        PMID: 30956174      PMCID: PMC6491797          DOI: 10.1016/j.ebiom.2019.03.062

Source DB:  PubMed          Journal:  EBioMedicine        ISSN: 2352-3964            Impact factor:   8.143


× No keyword cloud information.
In the version of this article originally published, in Supplementary Tables 1 and 2 CP2 concentrations were incorrectly presented in μM instead of nM. Tables are included here to reflect correct values including additional data for independent concentration evaluation. The mistake was introduced due to an error in the concentration of the standard used for the HPLC quantification. Additionally, in the Results section, the sentence “Average concentration of CP2 in the brain of new-born mice was ~90 μM, and in adult mice ~130 μM …” should be replaced with: “Average concentration of CP2 in the brain of new-born mice was ~90 nM, and in adult mice ~130 nM …”. Since CP2 was used as a model compound for a proof of concept studies, this mistake will not impact any preclinical developments.
  5 in total

1.  Partial inhibition of mitochondrial complex I ameliorates Alzheimer's disease pathology and cognition in APP/PS1 female mice.

Authors:  Andrea Stojakovic; Sergey Trushin; Anthony Sheu; Layla Khalili; Su-Youne Chang; Xing Li; Trace Christensen; Jeffrey L Salisbury; Rachel E Geroux; Benjamin Gateno; Padraig J Flannery; Mrunal Dehankar; Cory C Funk; Jordan Wilkins; Anna Stepanova; Tara O'Hagan; Alexander Galkin; Jarred Nesbitt; Xiujuan Zhu; Utkarsh Tripathi; Slobodan Macura; Tamar Tchkonia; Tamar Pirtskhalava; James L Kirkland; Rachel A Kudgus; Renee A Schoon; Joel M Reid; Yu Yamazaki; Takahisa Kanekiyo; Song Zhang; Emirhan Nemutlu; Petras Dzeja; Adam Jaspersen; Ye In Christopher Kwon; Michael K Lee; Eugenia Trushina
Journal:  Commun Biol       Date:  2021-01-08

Review 2.  Alcohol-Induced Neuroinflammatory Response and Mitochondrial Dysfunction on Aging and Alzheimer's Disease.

Authors:  Brandon Emanuel León; Shinwoo Kang; Gabriela Franca-Solomon; Pei Shang; Doo-Sup Choi
Journal:  Front Behav Neurosci       Date:  2022-02-10       Impact factor: 3.558

Review 3.  Mitochondrial complex I as a therapeutic target for Alzheimer's disease.

Authors:  Eugenia Trushina; Sergey Trushin; Md Fayad Hasan
Journal:  Acta Pharm Sin B       Date:  2021-11-09       Impact factor: 11.413

Review 4.  Targeting whole body metabolism and mitochondrial bioenergetics in the drug development for Alzheimer's disease.

Authors:  Steven N Austad; Scott Ballinger; Thomas W Buford; Christy S Carter; Daniel L Smith; Victor Darley-Usmar; Jianhua Zhang
Journal:  Acta Pharm Sin B       Date:  2021-06-30       Impact factor: 11.413

5.  A genome-wide association study in human lymphoblastoid cells supports safety of mitochondrial complex I inhibitor.

Authors:  Huanyao Gao; Utkarsh Tripathi; Sergey Trushin; Lela Okromelidze; Nicholas P Pichurin; Lixuan Wei; Yongxian Zhuang; Liewei Wang; Eugenia Trushina
Journal:  Mitochondrion       Date:  2021-02-19       Impact factor: 4.160

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.